Dale Yuzuki, Director of Digital and Strategic Marketing Communications at Olink Proteomics
0:00 A brief history-the proteome isn’t new!
9:00 Landmark 2014 paper
12:57 Why did it take so long for proteomics to scale?
18:42 Are proteomics companies doing true discovery?
26:35 What is the protein adding?
30:58 Proof of principle
37:50 Challenges ahead
It’s the age of multi omics. Or multi comics, if you don't catch spell check. A few weeks ago at the annual meeting of the American Society for Human Genetics, we were pleased to find not only genomics companies but some proteomics outfits finding a home. As we chatted with one of these, Olink Proteomics, we were blown away to hear that they were announcing the publication of 1,000 scientific papers. It wasn’t so long ago that genomics companies were boasting this kind of milestone. Has proteomics finally achieved scale?
Here to tell us is Dale Yuzuki, Director of Digital and Strategic Marketing Communications at Olink. He says in today’s interview that the proteome is now delivering on the original promise of the genome.
“There’s going to be a flurry of very significant findings with regard to the development of new drugs, new diagnostics, a new understanding of disease, new ways of prevention because of the genome project—ALL from new ways of analyzing the proteome at scale."
Dale is a return champion here on the program. He has worked for major life science tools and diagnostics companies, including Qiagen, Illumina, and Thermo. We ask him today why it took proteomics so long to scale? Olink is a Swedish company with a rich history in life science. They have just published a large scale study using the UK Biobank’s rich data resources.
